Table 3.

Clinical application of NDV (Part I).

1. Post-operative application of NDV oncolysate vaccines in Stage II melanoma (n = 83) by WA Cassel and DR Murray (1977) (oncolytic strain 73 T)

2. Systemic treatment of advanced chemorefractory cancers; Phase II placebo-controlled trial (n = 33 versus 26 controls) by LK Csatary and S Eckhardt (1993) (oncolytic strain MTH/68)

3. Systemic treatment of glioblastoma multiforme (GBM) (n = 14); Intra-patient dose escalation followed by 3 cycles of 55 billion infectious units by AI Freeman and Z Zakay-Rones (2006) (lentogenic strain HUJ)

4. Phase I dose-escalation trials of intravenous virus administration in patients with advanced solid cancers resistant to standard therapy (n = 113) by AL Pecora and RM Lorence (2002, 2003) (oncolytic strain PV71)

5. Post-operative treatment with the irradiated live tumor cell vaccine Autologous Live NDV-Modified Tumor Cell Vaccine (ATV-NDV): (i)Early breast cancer (n = 63), metastatic breast cancer (n = 27) and metastatic ovarian cancer (n = 31) by T Ahlert and V Schirrmacher (1997) (lentogenic strain Ulster) (ii)Phase II trial in patients with locally advanced colorectal carcinoma (CRC) (n = 57) by D Ockert and V Schirrmacher (1996) (lentogenic strain Ulster) (iii)Phase II trial in patients with GBM (n = 23 versus 87 non-vaccinated patients from the same clinic in the same time interval) by HH Steiner and C Herold-Mende (2004) (lentogenic strain Ulster) (iv)Phase I/II trial patients with Stage III and IV head and neck squamous cell carcinomas (HNSCC) (n = 20) by J Karcher and G Dyckhoff (2004) (lentogenic strain Ulster)

6. Prospectively randomized Phase II/III trial to investigate the efficiency of ATV-NDV vaccination after liver resection for hepatic metastases of CRC as a tertiary prevention method (n = 51) by T Schulze and PM Schlag (2009) (lentogenic strain Ulster)